<DOC>
	<DOCNO>NCT00885196</DOCNO>
	<brief_summary>This study design provide efficacy safety data several dos AEB071 optimal dose treatment duration choose test late study patient plaque psoriasis ( disease severity systemic treatment justify ) . The treatment free Follow-up Period design provide additional safety data information disease recurrence last dose study drug .</brief_summary>
	<brief_title>A Dose Finding Study AEB071 Assessing Psoriasis Area Severity Index Patients With Plaque Psoriasis</brief_title>
	<detailed_description />
	<mesh_term>Psoriasis</mesh_term>
	<criteria>Moderate Severe Plaque psoriasis diagnose least 12 month ( without psoriatic arthritis comorbidity ) require systemic therapy Severity disease meeting follow three criterion : PASI score 10 great Total Body Surface Area ( BSA ) affect plaque psoriasis 10 % great Investigator 's Global Assessment ( IGA ) score 3 great Hematological abnormality Heart rate &lt; 50 &gt; 90 bpm rest 5 minute Family history long QT syndrome History tachyarrhythmia History conduction abnormality i.e. , PR &gt; 200 msec , 2nd 3rd degree AV block , complete leave right branch bundle block , preexcitation syndrome Uncontrolled unstable angina pectoris ; history myocardial infarction within previous 12 month Known history congestive heart failure History percutaneous coronary intervention ( PCI ) cardiac ablation History stroke transient ischemic attack ( TIA ) Implanted cardiac pacemaker defibrillator History malignancy organ system Current guttate , generalize erythrodermic , pustular psoriasis Current drug associate psoriasis Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Psoriasis</keyword>
	<keyword>plaque psoriasis</keyword>
	<keyword>inflammatory skin disease</keyword>
	<keyword>scaly patch</keyword>
	<keyword>AEB071</keyword>
</DOC>